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Male breast cancer (MBC) occurs at less than 1% frequency of female breast 
cancer, and its actual etiology is still unclear. We hypothesize that males are protected 
from contracting breast cancer because the male-specific region of the human Y 
chromosome (MSY) has breast tumor suppressive function. Here, we show via 
fluorescence in situ hybridization (FISH) and droplet digital PCR (ddPCR) that Y 
chromosome was lost clonally at a frequency of ~15% (5/32) in two independently 
collated cohorts of MBC patients. We also show via FISH that this clonal Y loss occurred 
since ductal carcinoma in situ (DCIS) stage of MBC.  
Furthermore, we investigated regional loss of the Y chromosome in MBC patients 
who retained their Y chromosomes with STS-PCR (sequence-tagged-site PCR), derived 
from the male specific region of the Y chromosome Breakpoint Mapper (MSY-BPM), 
and showed nullisomic loss of TMSB4Y in a MBC patient. We showed via 
immunohistochemistry (IHC) that TMSB4Y is expressed in normal male breast tissue. 
Dox-inducible cell lines of TMSB4Y, TmY1 and TmY2, were generated in the female 
breast epithelial cell line MCF-10A background. Dox-induced expression of TMSB4Y 
resulted in altered morphology and reduced cell proliferation. Furthermore, reverse phase 
protein array (RPPA) analysis on TmY1 showed reduced expression of Syk (spleen 
tyrosine kinase) after Dox-induced expression of TMSB4Y.  
Interestingly, though TMSB4Y is highly homologous to its homologue TMSB4X 
on the X chromosome, the TMSB4Y antibody is solely specific to TMSB4Y, which 
suggests differences between TMSB4Y and TMSB4X.  
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Taken together, our results suggest that in situ clonal loss of human Y 
chromosome might contribute to MBC tumorigenesis, and that TMSB4Y is tumor 
suppressive through regulating breast cell morphology and reducing cell proliferation. 
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Male breast cancer (MBC) is a rare disease 
 Male breast cancer (MBC) is a rare disease that occurs at a frequency of less than 
1% of female breast cancers, and MBC makes up less than 1% of all cancers in men [1-
3]. In the United States of America, an annual average of about 200,000 females will be 
diagnosed with FBC, and only about 2000 males will be diagnosed with MBC [4, 5]. 
Internationally, MBC is proposed to occur at a proposed average incidence rate of <1 per 
100,000 men per year [6]. Here, the cancer incidence rate is calculated as the number of 
new global cases of MBC per 100,000 men per year. After analyzing statistics across the 
continents of Asia, Europe, America, and Oceania, MBC incidence rate is the highest in 
Israel (1.24 per 100,000 per year) and the lowest in Thailand (0.16 per 100,000 per year). 
Furthermore, recent epidemiological MBC studies showed a steady increase in annual 
occurrence [2, 7, 8]. 
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Interestingly, Klinefelter patients, who are males with an extra X chromosome, 
are reported to have elevated risks for MBC [9].  
This unbalanced statistical occurrence of breast cancer resulted in a female biased 
availability of breast cancer research resources as well. Based on the established MBC 
frequency, pathological tissue banks will have 100 times less MBC tumor formalin-fixed 
paraffin embedded (FFPE) tissue deposits. Such rarity of MBC tissue samples at each 
individual institution across the world has resulted in very recent consolidation efforts 
such as the Male Breast Cancer Pooling Project led by the National Cancer Institute [10]. 
Such collation projects is ongoing and will take a long time due to the complexity of 
approval protocols of various institutions and countries. 
Irrefutably, cancer cell lines are crucial to the progress of cancer research [11]. 
The first breast cancer cell line established was BT-20 [12], and then widely used breast 
cancer cell lines include the MDA-MB-coded MD Anderson series and the MCF-7 
established by the Michigan Cancer Foundation [13, 14]. To date, the American Type 
Culture Collection (ATCC) has 58 human mammary gland/breast cell lines available in 
their comprehensive catalogue, and all of them are of female origin. We managed to 
acquire one single MBC cell line, COLO-824, available at the Leibniz-Institut DSMZ - 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in 
Germany. However, we were unable to validate its identity from its signature Rb1 
deletion, which was documented in the Catalogue of Somatic Mutations in Cancer 





MBC versus female breast cancer 
Generally, MBC has a higher age of onset across Western, Middle Eastern, and 
South Asia compared to female breast cancer [15-17]. Unlike female breast cancer, MBC 
does not plateau after men become older than 50 years old and ethnically, more blacks 
than whites in the United States of America [18, 19]. 
Because of the rarity of MBC, most research studies are based on female breast 
cancer, and results are generally extrapolated into MBC clinical diagnosis and treatment  
[15]. However, clinical data from female breast cancer might not be entirely applicable to 
men since the etiology of MBC is still unclear, and studies have shown clinical and 
molecular differences in MBC when compared to female breast cancer. 
Clinically, surgical management of breast cancer is different in males and 
females. According to an analysis of 35 years of data (1973 to 2008) queried from the 
Surveillance, Epidemiology, and End Results (SEER) database, a majority of males with 
MBC with localized breast cancer (contained in breast) received mastectomy despite 
equivalent cause specific survival with lumpectomy or radiation therapy. In MBC, post 
mastectomy radiation therapy is not utilized extensively for patients with regional breast 
cancer (cancers in chest wall, skin, and regional lymph nodes) [20]. In general, it is noted 
that a majority of males usually do not opt for breast-conserving surgeries [21, 22]. 
Molecularly, breast cancers are traditionally classified according to their receptor 
status, namely Estrogen Receptor (ER), Progesterone Receptor (PR), and Her2 
(Epidermal Growth Factor Receptor 2). Females are exposed to hormonal cycles of 
estrogen and progesterone and it is logical for female breast cells express ER and PR, and 
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also for the ER+ and/or PR+ female breast cancer cells to maintain their expression. 
Interestingly, despite the lack of hormonal cycles in males, more than 75% of MBC is 
ER+ and/or PR+ [21, 22]. 
The current conceptual molecular subtyping of breast cancer combines 
information of the receptor status and tumor grade into several classes, namely 
Basal-like (Triple Negative), Luminal A (low grade and ER+), Luminal B (high grade 
and ER+), Luminal ER-/AR+, Her2+, and Normal-breast-like [23]. Claudin-low is a 
recently added molecular subtype that have opposite expression of tight junction genes 
(low) and epithelial-to-mesenchymal transition genes (high) [24]. These molecular 
subtypes were established mostly based on female breast cancer studies. Averaging 
across a few studies that grouped MBC cases accordingly, MBC mostly fall into Luminal 
A (~80%), some in Luminal B (~15%), and very few that are Basal-like (<5%) or Her2+ 
(<5%) [25-29]. Female breast cancers mostly fall into Luminal A (71%), some in Basal-
like (16%), and very few in Luminal B (6%) and Her2+ (6%) [30]. Interestingly, the 
percentages of Luminal B and Basal-like seem opposite for male and female breast 
cancers. 
 Recent sophisticated studies also highlight global genomic, transcriptomic, and 
proteomic differences between female and male breast cancers. Global gene expression 
profiling showed differences in at least 1000 genes between female and male breast 
cancers [31]. Using a computer framework called COpy Number and EXpression In 
Cancer (CONEXIC), cancer driver genes were shown to be largely different between 
male and female breast cancers as well [32]. 
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Physiologically, the human breast tissue lies behind the nipple on the chest wall. 
In males, it is generally considered non-functional, and also the total number of breast 
cells compared to females is significantly lower. Male breasts are not exposed to 
hormonal cycles like in females, but male breast cells do not escape genetic assaults like 
mutations that can lead to tumor formation. Since cancer is a genetic disease, and the 
fundamental genetic difference between males and females is the possession of the Y 
chromosome by males, genetics of the Y chromosome might play a role in why male 
breast cancer is a rare disease. 
 
The human Y chromosome is a genetic desert 
The human Y chromosome is one of the smallest human chromosomes, and it 
consists of 5% pseudoautosomal region (PAR) homologous to the X chromosome and 
95% of the male-specific region of the Y chromosome (MSY) [33]. The MSY is unique 
to males and only males have this genomic region. The MSY region was sequenced in 
2003, and it was revealed to be a mosaic of discrete euchromatic classes, namely 
X-transposed (99% identity to X chromosome), X-degenerate (ancient autosomal 
remnant sequences), and ampliconic (repetitive) [34]. Back then, they reported only about 
150 transcribed genes, with which only 80 are protein-coding, on the Y chromosome. 
Recent Y chromosome characterization has increased the total number of annotated genes 
to about 450 (according to the human genome map, National Center for Biotechnology 
Information), but the number of protein coding genes remain around 90 [35].  
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 The Y chromosome is best known for its role in sex determination and normal 
sperm production. SRY is the most well-known gene on the Y chromosome, and is 
established as the single determining factor for males [36]. Deletions of certain genomic 
loci on the Y chromosome is reported to cause azoospermic infertility in men [37]. 
 
Previous cytogenetic studies of MBC did not show in situ Y loss 
Previous early studies of MBC involved small case numbers, these include 
cytogenetic chromosome banding studies [38-40]. Even though the loss of Y 
chromosome had been reported as a nonrandom chromosome abnormality, results did not 
show in situ loss in tumor tissue. In these reports, the breast tumor tissues were 
dissociated, put through short term culture, and then underwent cytogenetic analysis. 
A recent 2013 study reported that loss of Y chromosome frequency was the same 
in their MBC patient group relative to their control group, and noted that this loss 
frequency increases sharply with age [41]. However, this study looked at sex 
chromosome aneuploidy in the peripheral blood of their human subjects. 









 Cancer is a genetic disease. Considering the fact that the human Y chromosome is 
the fundamental genetic difference between males and females, and that MBC is a rare 
disease, we hypothesize that the human Y chromosome is tumor suppressive in breast 
cancer. Therefore, we hypothesize that the loss of Y chromosome contributes to the 
tumorigenesis of MBC. According to our hypothesis, the human Y chromosome should 
contain breast specific tumor suppressive gene(s), which can be potential target(s) of 

















FFPE Tissue of MBC patients 
A total of 32 informative MBC patients were collated from 2 independent cohorts. 
Cohort 1 consisted of 15 MBC patients from the tumor tissue bank of Pathology 
Department of the Johns Hopkins Medical Institutes. Formalin-fixed paraffin embedded 
(FFPE) tissue blocks were available and samples were manufactured into a tissue 
microarray (TMA) for analysis. Cohort 2 consisted of a total of 20 MBC patients; 1 has 
the same source as cohort 1; the remaining 19 were obtained from the United States 
Department of Veterans Affairs. For cohort 2, only FFPE tissue slides were available, and 
3 out of 20 MBC patients were uninformative due to the quality of FFPE tissue. Thus, 






Fluorescence in situ hybridization (FISH) 
FFPE tissue slides were de-paraffinized by melting paraffin at 65°C for 5min, 
washed with Xylene for 3x15min, 100% EtOH for 2x5min, and air dried. Briefly, slides 
were pretreated, hybridized with FISH probes, and then mounted for microscope 
observation. Pretreatment was performed using Pretreatment Kit I (Abbott Molecular 
02J02-032). Slides were submerged for 20min in 0.2N HCl at RT, followed by 30min in 
Pretreatment Buffer (NaSCN) at 80°C, and then 16min in reconstituted protease solution 
at 37°C, rinsing and washing with diH2O and 2XSSC in between transitions. Slides were 
then dehydrated through 70%, 95%, then 100% EtOH, and dried for at least overnight. 
Probes were mixed with LSI/WCP Hybridization Buffer (Abbott Molecular 06J67-001) 
and heated to 45°C before being applied to tissue slides, which were denatured for 5min 
using the Statspin® Thermobrite slide processing system, and incubated at 37°C for 
48hrs in a humidity chamber. Slides were then washed in post-hybridization buffer (0.3% 
IGEPAL CA-630, Sigma 18896, in 2XSSC) for 4min at RT and then 3min at 75°C, 
counterstained with DAPI, and mounted with ProLong® Gold (Invitrogen, P36930). All 
fluorescence microscopy photos were imaged with NIS-Elements BR2.30. FISH probes 
used were all from Abbott Molecular: Vysis CEP X (DXZ1) SO Probe (Centromeric, 
05J08-033), Vysis CEP X (DXZ1) SA Probe (Centromeric, 05J09-033), Vysis CEP Y 
(DYZ1) SGn Probe (q arm, 05J10-034), Vysis CEP Y (DYZ3) SO Probe (Centromeric, 






Droplet Digital PCR (ddPCR) 
Droplet digital PCR (ddPCR) was performed using the QX100™ Droplet Digital 
PCR System according to the manufacturer’s recommendations (BioRad, Hercules, CA), 
as previously described [42]. TaqMan® Copy Number Assays (Life Technologies) used 
were Hs00314226_cn (FAM labeled) for XK gene on the X chromosome and 
Hs04125506_cn (VIC labeled) for EIF1AY gene on the Y chromosome. The positive 
control gDNA (Promega) used were male human gDNA (G1471) and female human 
gDNA (G1521). ddPCR was performed with the BioRad’s recommended two-step 
thermo-cycling protocol with a 58°C annealing/extension step. All data analysis was 
performed using QuantaSoft (BioRad). 
 
gDNA extraction from FFPE tissue slides 
Patient tissue slides were first stained with hematoxylin and eosin using standard 
techniques and our pathologist circumscribed areas of tumor versus normal tissue. Serial 
tissue slides were de-paraffinized as in our FISH protocol, and pinpoint solution (Zymo 
Research, D3001-1) was applied specifically onto the tumor versus normal tissue areas. 
Genomic DNA was then extracted and purified from the dried pinpointed tissue areas 




Male specific region of the Y chromosome Breakpoint Mapper (MSY-BPM) [43] 
was used to analyze the sequence-tagged sites (STS) status of gDNA extracted from 
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patients. 33 sets of STS primers that cover the MSY region (Table 2) and standard PCR 
conditions described were used to amplify STSs from gDNA extracted from tumor and 
normal tissue from breast cancer patients. PCR products were then ran on a 1% agarose 
gel, and the presence and absence of the STS amplicons were compared between the 
tumor and normal gDNA. For every set of STS-PCR (33 PCR reactions), a positive 
control (gDNA from a healthy anonymous male) and a negative control (gDNA from a 
female cell line MCF-10A) were performed synchronously to ensure integrity of PCR 
reactions. Each set of STS-PCR was repeated 5 times for reproducibility. 
 
Cell culture 
TetHyg2.5, derivative of the nontumorigenic human breast epithelial cell line 
MCF-10A [44] was grown in DMEM/F12 (1:1) supplemented with insulin at 10 µg/mL, 
hydrocortisone at 0.5 µg/mL, and cholera toxin at 0.1 µg/mL (hereafter denoted as 
“supplemented DMEM/F12”), 5% horse serum (Gibco), EGF at 20 ng/mL, and 
hygromycin at 14.3 µg/mL. Dox-inducible TetHyg2.5 derivatives (EV, TmY1, TmY2, 
and UA3) were grown in supplemented DMEM/F12 with 5% Tet-free FBS (HyClone), 
EGF at 20 ng/mL, hygromycin at 7.15 µg/mL, and G418 at 120 µg/mL. 293 cells were 
grown in DMEM media with 5% FBS. All supplements were purchased from Sigma-
Aldrich unless otherwise specified. MCF-10A and 293 cells were purchased from 






Generation of Dox-inducible clones 
TetHyg2.5 cells were seeded at about 50% confluency in a T25 flask in 
supplemented DMEM/F12 with 5% Tet-free FBS (HyClone), EGF at 20 ng/mL, 
hygromycin at 14.3 µg/mL on day 0; cotransfected with pBI-EGFP vector (with TMSB4Y 
cloned in) and 6A vector (gives Neomycin resistance) on day 1; changed to selection 
media (supplemented DMEM/F12 with 5% Tet-free FBS (HyClone), EGF at 20 ng/mL, 
hygromycin at 7.15 µg/mL, and G418 at 120 µg/mL) on day 2. On day 5, all cells were 
replated into ten 96-well plates and observed for single-well clones that express GFP 
upon Dox-induction at 2ug/ml, for 48hrs. The single well clones were then expanded and 
characterized. EV (empty pBI-EGFP vector) was generated as a negative control cell line, 
and TmY1 and TmY2 were generated as Dox-inducible cell lines to express TMSB4Y. 
 
Immunoblotting 
For Dox-induction assays, TetHyg2.5 and its derivatives were seeded in 
respective media with and without Dox for 48hours before harvesting. For transient 
expression assays, 293 cells were transfected with expression vectors for TMSB4Y, 
TMSB4X, or FLAG-TMSB4X , and harvested 48hrs after transfection. Whole-cell protein 
lysates prepared using Laemmli sample buffer were resolved by SDS-PAGE using 
NuPAGE gels (Invitrogen), transferred to 0.2 µm pore size Invitrolon polyvinylidene 
difluoride (PVDF) membranes (Invitrogen), and probed with primary antibody followed 
by incubation with horseradish peroxidase-conjugated secondary antibodies. The primary 
antibodies used in this study include anti-TMSB4Y (clone 6G4) mouse monoclonal 
antibody (SAB1403013; Sigma Aldrich), anti-TMSB4X mouse antibody (SAB1406539; 
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Sigma Aldrich), anti-TMSB4X (clone 4H7) mouse monoclonal antibody (H00007114-
M03; Abnova), anti-FLAG M2 antibody (200472-21; Agilent), anti-rabbit IgG 
HRP-linked antibody (7074, Cell Signaling Technology), anti-mouse IgG HRP-linked 
antibody (7076, Cell Signaling Technology), and anti-GAPDH (D16H11) XP rabbit 
monoclonal antibody (5174; Cell Signaling Technology). Specific RPPA antibodies 
(according to the RPPA standard antibody list) used include anti-Syk mouse monoclonal 
antibody (sc1240, Santa Cruz), anti-Rictor (53A2) rabbit monoclonal antibody (2114, 
Cell Signaling Technology), anti-ATP5H mouse monoclonal antibody (ab110275, 
Abcam), anti-PDGF Receptor β (28E1) rabbit monoclonal antibody (3169, Cell Signaling 
Technology), anti-PREX1 rabbit polyclonal antibody (ab102739, Abcam), and anti-
PCNA mouse monoclonal antibody (ab29, Abcam). 
 
Cell line tissue block 
Cells were trypsinized and fixed in 10% buffered formalin overnight. Thereafter, 
cells were spun down and resuspended with minimal (1:1) 1X PBS, then mixed via 
pipetting with 2% agarose solution. Various mixtures solidified after 5minutes forming 
agar plugs, which were placed in 6-compartment tissue cassettes and processed into 









Immunohistochemistry was performed on de-paraffinized (as in FISH protocol) 
patient tissue slides and the cell line tissue slides using the PowerVision + Poly-HRP 
anti-Mouse IHC Dectection System (Immunovision). Briefly, slides were steamed for 
40min in EDTA solution (Zymed) and incubated with anti-smooth muscle actin antibody 
mouse monoclonal (1:800 dilution, DAKO, m0851) or anti-TMSB4Y (clone 6G4) mouse 
monoclonal antibody (1:200 dilution, SAB1403013; Sigma Aldrich) overnight at 4°C. 
Poly-HRP anti-mouse IgG antibody was applied for 30min, and then visualized with 3,3’-
diaminobenzidine (Sigma) as the chromogen. Finally, slides were counterstained with 
hematoxylin. TBST rinses were performed in between steps. 
 
Cell proliferation assay 
Exponentially growing TetHyg2.5 cells were washed with HBSS twice and 
seeded in supplemented DMEM/F12 with 1% Tet-free FBS (HyClone), EGF at a 
physiological dose of 0.2 ng/mL, and hygromycin at 14.3 µg/mL. TetHyg2.5 and Dox-
inducible TetHyg2.5 derivatives (EV, TmY1, and TmY2) were seeded in supplemented 
DMEM/F12 with 1% Tet-free FBS (HyClone), EGF at a physiological dose of 0.2 
ng/mL, hygromycin at 7.15 µg/mL, and G418 at 120 µg/mL. Dox induction was done by 
seeding cells with the respective media with 2µg/mL of Dox. 2 x 104 cells per well of a 
6-well tissue culture dish on day 0. Medium was changed every third day, and cells were 
harvested for cell counting on days 3, 6, 7, 13, and 18 using a Beckman Coulter® Vi-
CELL™ XR Cell Viability Analyzer. On matched days, cell counts of Dox-induced cells 




All statistical analyses were conducted with GraphPad Prism software. For the t-
tests conducted, P<0.05 was considered significant. 
 
Reverse phase protein array (RPPA) 
Cell lines TeHyg2.5, EV, and TmY1 were grown in 6-wells with and without 
Dox-induction for 48hrs, and lysates were harvested at a confluency of 80% to 90% using 
the lysis buffer and 4X SDS sample buffer provided by the RPPA Core Facility – 
Functional Proteomics of the MD Anderson Cancer Center, University of Texas. Lysates 
were prepared strictly accordingly to the protocol provided by the RPPA Core Facility. 
Briefly, cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol) and 
diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% SDS). 
Serial diluted lysates were arrayed on nitrocellulose-coated slides (Grace Biolab) by 
Aushon 2470 Arrayer (Aushon BioSystems). Total 5808 array spots were arranged on 
each slide including the spots corresponding to positive and negative controls prepared 
from mixed cell lysates or dilution buffer, respectively. Each slide was probed with a 
validated primary antibody plus a biotin-conjugated secondary antibody. Only antibodies 
with a Pearson correlation coefficient between RPPA and western blotting of greater than 
0.7 were used in reverse phase protein array study. Antibodies with a single or dominant 
band on western blotting were further assessed by direct comparison to RPPA using cell 
lines with differential protein expression or modulated with ligands/inhibitors or siRNA 
for phospho- or structural proteins, respectively. The signal obtained was amplified using 
a Dako Cytomation–catalyzed system (Dako) and visualized by DAB colorimetric 
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reaction. The slides were scanned, analyzed, and quantified using a customized-software 
Microvigene (VigeneTech Inc.) to generate spot intensity. Each dilution curve was fitted 
with a logistic model (“Supercurve Fitting” developed by the Department of 
Bioinformatics and Computational Biology in MD Anderson Cancer Center, 
“http://bioinformatics.mdanderson.org/OOMPA”). This fits a single curve using all the 
samples (i.e., dilution series) on a slide with the signal intensity as the response variable 
and the dilution steps are independent variable. The fitted curve is plotted with the signal 
intensities – both observed and fitted - on the y-axis and the log2-concentration of 
proteins on the x-axis for diagnostic purposes. The protein concentrations of each set of 
slides were then normalized by median polish, which was corrected across samples by the 
linear expression values using the median expression levels of all antibody experiments 












Clonal loss of Y chromosome in MBC 
To address the hypothesis that Y chromosome might have a protective role in 
breast cancer, we investigated the presence or absence of Y chromosome in MBC 
patients. A loss of Y chromosome would support our hypothesis of Y chromosome’s 
protective role in breast cancer. Here, we obtained FFPE tissue blocks of MBC tissue of 
15 patients (cohort 1), manufactured them into a tissue microarray (TMA), and analyzed 
the sex chromosome statuses by FISH (Fig. 1). To survey the entire Y chromosome, we 
used various combinations of sex chromosome enumeration FISH probes specific for the 
short arm, centromere, and long arm of the Y chromosome (Fig. 2), and we observed 
clonal loss of whole Y chromosome in ~13.33% (2 out of 15) MBC patients. Here, we 
are the first to report in situ clonal loss of Y chromosome in MBC, whereas previous 
cytogenetic reports [38-40, 45] did not show in situ clonal of Y loss. 
18 
 
Next, we obtained 20 more MBC patient FFPE slides, but only 17 MBC patients 
were informative (cohort 2). We were unable to obtain FFPE tissue blocks for these 
samples, we could not manufacture another TMA. Therefore, we analyzed gDNA 
extracted from these FFPE tissue serial slides with ddPCR, using taqman probes and 
primers specific to sex chromosomes (Table 1). The ratio of Y vs X taqman positive 
droplet signal (ratio Y/X) of our known Y loss patient (Patient 19) was 0.193, the residual 
Y signal in this sample was attributed to contamination of normal gDNA within the 
tumor tissue. Subsequently, a ratio Y/X of lower than ~0.2 is considered a most possible 
Y loss patient; a ratio Y/X of between ~0.2 to ~0.4 is considered a probable Y loss 
patient; and a ratio Y/X of higher than ~0.4 is considered a Y retention patient. gDNA 
from one patient (Patient 18) yielded uninformative ddPCR results. Using ddPCR as a 
first pass analysis, we observed 6 out of 17 analyzable MBC patients who have possible 
Y loss. FISH was performed successfully in 14 out of these 17 patients to validate the 
presence or absence of sex chromosomes. Among the 6 patients with the lowest Ratio 
Y/X (range of 0.0 to 0.4), and it is confirmed that the 2 MBC patients with Ratio Y/X 
smaller than 0.2 and 1 MBC patient with a Ratio Y/X of ~0.4 are Y loss cases. Therefore, 
for cohort 2, we observed clonal loss of Y chromosome in ~17.65% (3 out of 17) MBC 
patients. 
Combining results from the two independent cohorts of MBC patients, we 





Loss of Y chromosome in MBC since DCIS 
After observing the loss of whole Y chromosome in MBC tissue, we investigated 
whether Y was lost in the ductal carcinoma in situ (DCIS) stage of MBC. Therefore, we 
obtained DCIS tissue of one of the Y loss patients (Fig. 3A). An anti-smooth muscle actin 
stain verified that the tissue was DCIS (Fig. 3B), and we showed via FISH that Y was 
lost since DCIS, where the DCIS tissue has the absence of the Y chromosome while the 
adjacent stromal tissue retained the Y chromosome (Fig. 3C). 
 
Nullisomic loss of TMSB4Y in male breast cancer patient 
In MBC samples that retained the Y chromosome, Y FISH signals were aberrant 
in tumor cells compared to the surrounding stromal cells in the fibrous tissue (Fig. 1B, Y 
Probe panel). Thus, we hypothesized that the Y chromosome in MBC tumor cells might 
be chromosomally unstable, also based on previous studies that microdeletions are 
common within the Y chromosome [46-50]. To investigate this, we extracted gDNA of 
five MBC patients who retained the Y chromosome, and amplified 33 Sequence Tagged 
Sites (STSs) with standard PCR (Table 2, Fig. 4) within the MSY based on the MSY-BM 
[43]. Paired tumor vs normal gDNA (labeled by pathologist) were extracted from FFPE 
slides, and only three out of our five patients were analyzable due to the quality of the 
extracted FFPE gDNA. STS primer set S27 was not amplified from any FFPE gDNA, 
because the amplicon size is ~1kb and thus cannot be amplified from fragmented FFPE 
gDNA. 
Interestingly, STS primer S17 did not amplify at all for the tumor gDNA for one 
of the three analyzable MBC patients, but it amplified for his paired normal gDNA 
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(Fig. 5). STS primer S17 amplifies STS sY1230, which spans exon1 and intron 1 of 
TMSB4Y, the gene coding for an actin sequestering protein, Thymosin Beta 4, Y-linked. 
Therefore, our STS-PCR data showed the nullisomic loss of TMSB4Y in MBC the tumor 
gDNA of one of our MBC patients who retained the Y chromosome. 
 
TMSB4Y is expressed in normal male breast tissue 
We performed immunohistochemistry for TMSB4Y on breast tissue of one of our 
patients who lost the Y chromosome in his breast cancer cells. In this patient, the normal 
acini were more strongly stained compared to the tumor tissue (Fig. 6), and any faint 
staining in fibrous tissue and tumor cells was attributed to a low level of background 
nonspecific staining. This shows that TMSB4Y is expressed in normal male breast tissue, 
and apparently not expressed after the loss of Y chromosome. 
 
TMSB4Y expression alters breast epithelial cell morphology 
To investigate the effects of TMSB4Y in breast cells, we generated stable Dox-
inducible clones in the TetHyg2.5 cell line. TetHyg2.5 is MCF-10A that is engineered to 
permanently express the reverse Tet repressor; MCF10A is a genetically stable 
nontumorigenic breast epithelial cell line [44]. TMSB4Y was cloned into the bidirectional 
pBI-EGFP vector, which contains the Tet response element, and expresses GFP 
simultaneously with TMSB4Y. We generated TmY1 and TmY2, two Dox-inducible cell 
lines that express both GFP and TMSB4Y when induced with Dox. EV contains the pBI-
EGFP empty vector and expresses only GFP when induced with Dox. Expression of 
TMSB4Y after Dox-induction was verified via western blotting (Fig. 7A) and 
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immunohistochemistry (IHC) on tissue cell blocks made from the generated cell lines 
(Fig. 7B). Apparently, TmY1 has stronger induction of TMSB4Y compared to TmY2. It is 
noteworthy that transient expression of GFP in MCF-10A cells is non-toxic (Fig. 8). 
Dox-induction of TMSB4Y changes the morphology of TmY1 and TmY2 cell 
lines drastically (Fig. 9A), where cells become enlarged and distorted. Furthermore, 
F-actin staining after Dox-induction of TmY1 confirms this alteration in cell morphology 
(Fig. 9B). 
 
TMSB4Y expression reduces cell proliferation 
In Fig. 10A, Dox-induction of TMSB4Y significantly reduced the growth rates of 
TmY1 and TmY2 by about 30% when compared to TetHyg2.5 and EV (P < 0.05) in a 6-
day growth assay, where cell counts of Dox-induced cells were plotted as a percentage of 
cell counts of non-induced cells. This reduction is proliferation was also observed in a 
detailed growth assay where cell counts were taken on days 0, 3, 7, 13, and 18 (Fig. 10B). 
 
Syk expression is reduced after Dox-induced TMSB4Y expression 
In order to find the possible cause of the effects of TMSB4Y expression on cell 
morphology and proliferation, we utilized reverse phase protein array (RPPA) to 
investigate global protein expression changes in TmY1 after Dox-induction. The change 
in expression of other proteins might allow us to tease out genetic pathways regulated by 
TMSB4Y. TetHyg2.5 and EV were analyzed with RPPA as negative controls. The RPPA 
heatmap (Fig. 11A) indicates relative protein expression by a color pattern, where green 
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equates to low expression, and red equates to high expression. We are interested only in 
protein candidates that are either noticeably increased or decreased for only TmY1+Dox, 
and then a similar color pattern for the rest of the samples (TetHyg2.5, TetHyg2.5+Dox, 
EV, EV+Dox, TmY1). According to this observation pattern, 6 protein candidates were 
noted. Expression of Rictor was increased, whereas the expression of Syk, ATP5H, 
PCNA, PDGFRβ, and Prex1 were decreased. Their specific antibodies (according to the 
RPPA standard list) were utilized to validate the RPPA results. For 5 protein candidates, 
expression difference was either too subtle, or the antibodies exhibited high 
non-specificity towards our lysates. Eventually, we were only able to validate the reduced 
expression (P<0.05) of Syk (spleen tyrosine kinase) after Dox-induced expression of 
TMSB4Y in both TmY1 and TmY2 (Fig. 11B).  
 
TMSB4Y is different from its homologue TMSB4X 
TMSB4Y has an X-linked homologue TMSB4X, and they are different only by 
three out of 44 amino acids. However, their antibodies clearly do not cross-react, which 
shows that the three amino acid differences cause apparent differences between TMSB4Y 
and TMSB4X. We transiently expressed TMSB4X in 293 cells, and we did not observe 
any bands on western blots with our specific anti-TMSB4Y and also our two anti-
TMSB4X antibodies (results not shown). Therefore, we expressed FLAG-TMSB4X in 293 
cells, confirmed the expression of TMSB4X by blotting for FLAG, and then confirmed 






Figure 1. Clonal loss of Y chromosome in MBC 
A, Normal somatic male breast acinus has both X and Y sex chromosomes. 
B, Male breast cancer tissue that retained both X and Y sex chromosomes. 
C, Male breast cancer tissue that retained X chromosomes, lost the Y chromosome 
clonally in cancer tissue, but retained Y chromosome in surrounding somatic tissue. 







Figure 2. FISH probes for sex chromosomes 
In the schematic of the sex chromosomes, the Y-shaped figure represents the Y 
chromosome and the X-shaped figure represents the X chromosome.  
A, Various probes we used for both X and Y sex chromosomes. We have red probes for 
p-arm and centromere of Y chromosome; green probe for q-arm of Y chromosome; red 
and violet probes for centromere of X chromosome. 




S/No Patient ID 
Positive ddPCR Droplets 




01 0751724 3J 5 7 524 0.013 (F) Y Loss 
02 0251354 A 5 6 114 0.053 (F) Y Loss 
03 1154102 4A 5 357 1009 0.354 (F) Y Retention ** 
04 995209 C 5 217 566 0.383 (F) Y Retention ** 
05 0251134 A 5 84 205 0.410 (F) Y Loss 
06 0051749 P 5 54 116 0.466 Y Retention 
07 0752630 1D 5 47 73 0.644 (F) Y Retention 
08 0252481 B 5 17 24 0.708 (F) Y retention 
09 0251600 M 5 158 196 0.806 (F) Y Retention 
10 0453365 C 5 57 52 1.096 (F) Y retention 
11 9952907 H 5 134 117 1.145 (F) Y retention 
12 972005 L 5 334 214 1.561 (F) Y retention 
13 0854095 2F 5 482 293 1.645 (F) Y retention 
14 0953927 1d 5 156 91 1.714 Y retention 
15 1251936 4E 5 2067 1188 1.740 (F) Y retention 
16 115759 1T 5 53 23 2.304 Y retention 
17 S13 1824 252 86 2.930 (F) Y retention 
18 9651911 B 5 3 1 3.000 Uninformative 
19 06-70864 101 523 0.193 (F) Y Loss Patient 
20 Male gDNA 2628 2720 0.966 Male Control 
21 Female gDNA 0 3451 0.000 Female Control 
 
*(F) refers to FISH verified patients.  
** Denotes MBC patients who have duplication of X chromosome. 
Table 1. Y Loss in MBC Patients Shown via droplet digital PCR (ddPCR) 
Tumor gDNA was extracted from FFPE tissue slides of MBC patients and analyzed with 
ddPCR Taqman probes specific for X and Y chromosomes. Promega Male and Female 
gDNA were used as control for probe specificity; Patient 19 (from cohort 1) showed Y 
Loss and is as a gauge of the possible base level gDNA contamination from normal tissue 
during FFPE extraction. 14 out of 17 ddPCR-analyzable patients were validated with 







Figure 3. Clonal loss of Y chromosome in MBC since DCIS 
A, H&E Stain of a DCIS lesion of a male breast cancer patient who lost the Y 
chromosome in his cancer tissue. 
B, Anti-smooth muscle actin stain confirms that the well- circumscribed lesion is a DCIS 
lesion. 
C, DCIS lesion (left) retained X chromosomes, lost the Y chromosome clonally, but 
retained Y chromosome in adjacent somatic tissue (right). Red arrows point to the X-
probe signal and green arrow points to the Y-probe signal.  




S/No. STS Identifier Primer 1 Primer 2 
S01 sY1247 GAACTCTGCAAACCTCCTGG TTTTGAGGCGGAGTCTCG 
S02 sY14 GAATATTCCCGCTCTCCGGA GCTGGTGCTCCATTCTTGAG 
S03 sY274 TTAAGGGGACAGTATTTCAACTTC CCACATTTAAACTGAGTACAGTCC 
S04 sY238 AACAAGTGAGTTCCACAGGG GCAAAGCAGCATTCAAAACA 
S05 sY1254 GACCAATTTGTCTTTGTTGCG GCTGCTGAAGTCGGCGTA 
S06 sY1240 GGGTCCTAGATAGGCTCCAAG TTCATGTTGGCAGTGATTGG 
S07 sY276 CCTACCGCATCAGTGAATTTC TCTGTATGTGGAGTACACATGG 
S08 sY1238 GGTGTGCTAACATTGCATGG TTTGTTCCATTTCAGAGCGA 
S09 sY637 CCTGCCTTTTTTAGTTTCCAGCA TACTGTGATAGGTAGAATAATGGC 
S10 sY1319 ACCTGTCTGGGAAACACCTC GAGCCCTACAACCAGCTTCA 
S11 sY1250 TTTTTCTAACCTTGCCTGCG TGCAGAGAAGCAGCCTACAA 
S12 sY1251 GACTGGAGTGGAACGGTCTC TCACTTCCCTCCGATTTTCT 
S13 sY1317 GAGATTACAGGCATGCACCA CCACACTTAGCCCACAGTCA 
S14 sY1316 AAGGCAGGTCTGATGCATGT AAAGAAAGCTGCCTCATAGCA 
S15 sY1234 TTACCCCTTTCACCCACTGA CCATAAACTACACAAGGACGAACT 
S16 sY1231 TTGCACCCGTAGTCAAATGT ACCCACAACTCAAATCGTCT 
S17 sY1230 CTCTTCCAAGCCAGCCTTTA AACCTTTGCAAGCCACATTC 
S18 sY90 CAGTGCCCCATAACACTTTC ATGGTAATACAGCAGCTCGC 
S19 sY1239 CCTAGCTCTCTTTTTCTTGCAG CAAATATCGCCAGTGAGGCT 
S20 sY210 ATCACTTGGCAGCTTTTCC GCACTGCAACTTTTATGCCT 
S21 sY121 AGTTCACAGAATGGAGCCTG CCTGTGACTCCAGTTTGGTC 
S22 sY1322 TGGAAACATTCTCAACAGGGA GGCATTTCTCGCATGAGTTT 
S23 sY280 AACTGTACTCCTGGGTAGCCTG CTCCCGTGGGGATGAAGATAATA 
S24 sY1233 TCTCCGGTATCCTGATGGAG AAATAGGGCATTCCCAGCTC 
S25 sY1682 GGTTGCACCGTAAAAGGAGA GTCTGTCAAGACAGCGTCCA 
S26 sY142 AGCTTCTATTCGAGGGCTTC CTCTCTGCAATCCCTGACAT 
S27 sY1258 AACCCCATCTCTAGCAAAAATATG TAGGTGACAGGGCAGGATTC 
S28 sY1197 TCATTTGTGTCCTTCTCTTGGA CTAAGCCAGGAACTTGCCAC 
S29 sY1191 CCAGACGTTCTACCCTTTCG GAGCCGAGATCCAGTTACCA 
S30 sY1291 TAAAAGGCAGAACTGCCAGG GGGAGAAAAGTTCTGCAACG 
S31 sY1201 CCGACTTCCACAATGGCT GGGAGAAAAGTTCTGCAACG 
S32 sY1166 AGTCGGAGTCGGAGTGTGAT ATTCCATTGCTTTCCATTGC 
S33 sY1273 GAGCTGCAACATAACAGGCA AGGGGAACATCACACTCTGG 
 
Table 2. 33 Pairs of Landmark STS Primers within the MSY 
33 STSs spanning the male specific region of the human Y chromosome (MSY), as 





Figure 4. Amplicons of STS-PCR (Sequence-Tagged Sites PCR) 
The 33 pairs of MSY Breakpoint Mapper (MSY-BP) primers, S01 to S33, amplify 
sequence-tagged sites spread across the Male Specific Region of the Y chromosome 
(MSY). PCR was performed on gDNA extracted from a normal human male. The 
amplicon sizes range from 176bp to 968bp. S13 is uninformative; S12, S28, S32, and S33 







Figure 5. STS-PCR results of MBC patient 
A, Each STS-PCR is repeated 5 times on the matched tumor and normal FFPE gDNA 
from the patient. Each of the 33 sets of tumor vs normal STS-PCR is presented in a 
decagon. The relative segment of the decagon is filled only if the PCR reaction fired; 
tumor STS-PCR is filled with blue, represented by the five decagon segments on the left; 
normal STS-PCR is filled with red, represented by the five decagon segments on the 
right. 
B, Primer sets S13 and S27 are uninformative. A majority of the decagons are completely 
filled, which signifies that both tumor and normal gDNA retained that respective STS. 






Figure 6. TMSB4Y is expressed in normal male breast tissue 
Immunohistochemistry (IHC) for TMSB4Y was performed on breast tissue from a male 
breast cancer patient who lost his Y chromosome (shown previously via FISH). Normal 
acini are more strongly stained compared to tumor tissue, which has no staining above a 







Figure 7. Verification of TMSB4Y expression in Dox-inducible clones 
TMSB4Y is cloned into the pBI-EGFP vector and transfected into the TetHyg2.5 to make 
Dox-inducible clones. TmY1 and TmY2 express TMSB4Y upon Dox induction, shown 
via western blotting (A) and immunohistochemistry on tissue cell blocks (B). 
293 transient transfection is the positive control; TetHyg2.5 expresses the reverse Tet 







Figure 8. Transient expression of GFP in MCF-10A cells is non-toxic 
Transient expression of GFP in MCF-10A cells has no noticeable effect, as shown in 










Figure 9. TMSB4Y expression induces morphological changes 
Dox-induction expresses TMSB4Y in Dox-inducible clones, and results in aberrant 
morphological changes. 
A, Phase contrast and GFP images of TmY1 and TmY2 show enlargement and distortion 
of cells after Dox induction. 
B, F-actin staining of TmY1 confirms the aberrant morphological changes after Dox-
induction. 
TetHyg2.5 expresses the reverse Tet repressor and is derived from MCF-10A; EV is 













Figure 10. TMSB4Y expression reduces cell proliferation 
Dox-induction expresses TMSB4Y in Dox-inducible clones, and results in reduction in 
proliferation. 
A, TmY1 and TmY2 exhibited ~30% of reduced proliferation upon Dox induction 
(P < 0.05), after 6 days of growth. 
B, A persistent ~30% of reduced proliferation after Dox-induction in both TmY1 and 
TmY2 was observed in a detailed growth assay, with cell counts at Days 3, 7, 13, and 18.  
TetHyg2.5 expresses the reverse Tet repressor and is derived from MCF-10A; EV is 

















Figure 11. Syk expression is reduced after Dox-induced TMSB4Y expression 
Reverse phase protein array (RPPA) was utilized to investigate global protein expression 
patterns in TetHyg2.5, EV, and TmY1 before and after Dox-induction. 
A, RPPA heatmap. Green means low protein expression, and red means high protein 
expression. Syk expression is green only for TmY1+Dox. Therefore, Syk expression in 
TmY1 is reduced when TMSB4Y is expressed. 
B, Syk expression is reduced for both TmY1 and TmY2 after Dox-induced expression of 









Figure 12. TMSB4Y is different from its homologue TMSB4X 
TMSB4X is a gene on the X chromosome, and it only differs from TMSB4Y by three out 
of 44 amino acids. Here, we transiently expressed TMSB4Y and FLAG-TMSB4X in 293 
cells, and despite the close homology, our specific TMSB4Y antibody did not detect 











Cancer is a disease fundamentally caused by a successive series of genetic 
alterations that lead to selective proliferative advantages in a single starting cell, which 
expands into a tumorigenic clone. This classic “Vogelgram” model of sequential 
accumulation of carcinogenic mutations was first described in colorectal cancer, where 
progressive accumulation of mutations in APC (from normal to early adenoma), KRAS 
(from early to intermediate adenoma), SMAD4 (from intermediate to late adenoma), and 
then p53 which eventually leads to colorectal carcinoma [51]. All the cells that originate 
from this clone will retain specific genetic signatures acquired in this tumorigenic 
process. Therefore, our novel FISH report of in situ clonal loss of Y chromosome in 
MBC increases the weight of evidence that Y loss contributes to the tumorigenesis of 
MBC. 
Even though our total MBC sample size of 32 patients is small, it is noteworthy 
that the Y loss frequency is consistently ~15% in these 2 independent cohort of MBC 
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patients. Because there is an international effort to consolidate MBC samples that our 
research group is involved in, we anticipate to greatly expand our sample size to confirm 
this average frequency of ~15% clonal Y loss in MBC. 
Interestingly, we also saw the loss of Y chromosome in the DCIS tissue of one of 
our MBC patients who has clonal Y loss in his tumor tissue (Fig 3). DCIS slides were 
only available for 1 out of 5 of our Y loss patients. In consonant with the concept of 
progressive accumulation of genetic mutations in tumorigenesis, Y loss seems to have 
already happened since DCIS, which suggests that Y loss might be an early contributive 
oncogenic factor. However, since we only showed this in one MBC patient, this aspect of 
our study needs to be expanded after collation of more MBC samples with available 
DCIS tissue. 
FISH presents clonal Y loss clearly in situ, however, the success of FISH is 
dependent on the quality of the FFPE tissue. Therefore, we established a much more 
sensitive technique of droplet digital PCR (ddPCR) to analyze Y loss in MBC, as shown 
in our results in patients of cohort 2. However, we have to be cautious when analyzing 
ddPCR results. Here, we utilized the Y/X fluorescent ddPCR readout ratio to evaluate Y 
loss status in ddPCR. The loss of Y will skew the Y/X ratio towards zero. ddPCR is a 
very sensitive technique, and because there is always normal stromal cells and tissue 
around the tumor tissue, genomic DNA of these normal cells amongst tumor cells serves 
as contaminating ddPCR readouts. Our previous case study, where we established ddPCR 
as a tool to analyze loss of heterozygosity of BRCA2 alleles, also shows a basal level of 
contamination from surrounding normal stromal cells [52]. Therefore, when analyzing 
ddPCR results, we have to take this basal level of contamination from normal gDNA into 
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account, which is shown in our Y/X ratio. According to our Y/X ratios consolidated in 
Table 1, our three Y loss patients from cohort 2 have Y/X ratios of 0.013 (1.3%), 0.053 
(5.3%), and 0.41 (41%); our control Y loss patient has a Y/X ratio of 0.193 (19.3%). The 
high level of 41% contamination from normal stromal cells was unexpected, and when 
we relooked at the H&E section of the tumor area we selected for extraction, there was a 
high level of normal stromal cells, which explains this high level of contaminating Y 
readouts in a Y loss patient (validated by FISH). Therefore, caution has to be taken while 
selecting tissue areas on the FFPE slides for gDNA extraction. Targeted tumor areas for 
gDNA extraction should have a tumor cell population as pure as possible. A strict cutoff 
for Y/X ratio of below 0.010 (10%) should be established if only looking at ddPCR 
results. Any Y/X ratios between 0.010 (10%) to 0.040 (40%) should definitely be 
validated with FISH, otherwise, their Y loss status (based on ddPCR) is debatable. Here, 
we established ddPCR as a novel tool to evaluate Y loss in MBC, which should be 
utilized especially when MBC tissue is very limited, and a TMA (for FISH) of MBC 
samples is not available. 
Our ddPCR assay is able to indicate duplication of X chromosome in male breast 
tumor cells as well. In Table 1, two patients (S/No. 03 and 04) show duplicated X in 
tumor cells according to FISH, and their Y/X ratios from ddPCR are 0.354 (35.4%) and 
0.383 (38.3%), which seems to have almost double the X ddPCR readout compared to the 
Y ddPCR readout. Thus, our ddPCR assay indicates duplication of X in tumor cells when 
the Y/X ratio is around 0.35 (35%). Gaining an extra X chromosome might be a causative 
tumorigenesis factor too, which is in consonant with the concept of the report that 
Klinefelter patients (XXY) have a higher risk for MBC [9]. 
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Interestingly, recent studies have strongly suggested that the human Y 
chromosome has tumor suppressive functions that are still not elucidated. Mosaic loss of 
Y chromosome is now associated with a higher risk of non-hematologic cancers in men 
[53]. It is shown that men with non-hematologic cancers (such as throat, prostate, 
stomach), have a loss of Y chromosome in their peripheral blood. Furthermore, this loss 
of Y in peripheral blood in men is associated with smoking in a dose-dependent manner 
[54]. It has been well established for more than half a century that cigarette smoking 
causes many human diseases, which includes cancer, especially lung cancer [55]. 
Furthermore, male microchimerism in women was shown to reduce the risk of 
breast cancer to one third [56]. In fact, this male chimerism observed in the peripheral 
blood of women generally increases the survival of women affected by cancers and 
cardiovascular diseases [57]. Male microchimerism is a natural phenomenon that occurs 
in females who are or have been pregnant with a male fetus, and it happens when the 
male fetus exchanges cells with his mother via the placenta. Some of these male fetal 
cells presumably persist throughout the mother’s lifetime, for as long as almost three 
decades [58]. Very interestingly, these studies suggest that the presence of the Y 
chromosome in females is tumor suppressive without any known mechanism. 
In order to investigate putative tumor suppressive function of the human Y 
chromosome, the full Y chromosome was transferred into PC-3, a prostate cancer cell 
line that has Y loss, via microcell-mediated chromosome transfer (MMCT). This MMCT 
of the Y chromosome into PC-3 suppressed the formation of xenografts in 59 out of 60 
athymic nude mice. This further suggests that the Y chromosome contains some tumor 
suppressive element.  
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Taken together, previously described reports and our own report of clonal Y loss 
in MBC strongly suggest a tumor suppressive role of the human Y chromosome in human 
cancer. 
After seeing whole Y loss in 5 out of 32 (~15%) of our MBC patients, we 
proceeded to investigate regional loss of the Y chromosome in MBC patients who 
retained Y. The FISH signals for the Y chromosome are aberrant in the tumor cells of 
some of our MBC patients who retained Y, compared to the corresponding Y signals in 
the surrounding normal stromal cells (Fig. 1B). This led us to think that the retained Y 
chromosome underwent some form of structural rearrangement or deletions, and thus 
indicative of regional loss of genomic regions on the retained Y chromosome. Therefore, 
we proceeded to utilize STS-PCR (STS primer sets derived from MSY-BPM) to 
investigate regional Y loss in MBC patients who retained their Y chromosome.  
Using STS-PCR, we were able to show that STS17 was lost in the tumor gDNA 
in one of our MBC patients who retained Y. Because of the quality of the extracted FFPE 
gDNA, we were only able to analyze 3 out of 5 of the patients we extracted FFPE gDNA 
from. Our STS-PCR has certain limitations. Firstly, the quality of FFPE limits the success 
of our STS-PCR reactions. Secondly, the total amount of gDNA available from our FFPE 
extractions were also limited. Thirdly, formalin fixing and paraffin embedding degraded 
the tissue gDNA and thus, the amplicon sizes of our STS-PCRs have to be relatively 
short, leading to a couple of STS primer sets with amplicon sizes of about 1kb to become 
uninformative. In future, we look forward to optimize the STS primer sets that cover the 
MSY region for the highly sensitive ddPCR, and develop STS-PCR into STS-ddPCR. 
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Eventually, using STS-PCR, we showed focal nullisomic loss of STS17 in one of 
our MBC patients. STS17 is located within the gene TMSB4Y. To increase the argument 
that TMSB4Y is a deleted tumor suppressor gene, we surveyed public databases of 
sequenced tumors via cBioPortal, a web-based tool that allows analysis of publicly 
available next-generation sequencing data of tumors, and discovered that TMSB4Y was 
reportedly deleted in 10 out of 61 prostate cancer samples with known copy number 
alteration profiles [59]. Furthermore, a previous study has shown via array comparative 
genomic hybridization (aCGH) a 40% (10/25 patients) deletion of Yq11.1-q11.221in 
MBC, and this Yq region contains TMSB4Y [60]. 
So far, all these TMSB4Y deletion data is shown at the DNA level, which is 
provocative, because if TMSB4Y is a genuine tumor suppressor gene, it should be 
expressed at the protein level in normal male breast tissue. And we managed to show that 
TMSB4Y is expressed in normal male breast tissue via IHC (Fig. 6), which suggests that 
TMSB4Y has a normal functional role in normal male breast epithelial cells. 
Not much is known about TMSB4Y itself, except that based on gene sequence, it 
codes for the Y homologue of an actin monomer sequesterer called Thymosin Beta 4 
[61]. Interestingly, TMSB4Y was reported to have an unconventional open reading frame 
that codes for a novel minor histocompatibility antigen [62]. Thymosin Beta 4 is also 
reported to enhance natural killer cell cytotoxicity [63]. Interestingly, TMSB4Y has a 
homologue on the X chromosome, TMSB4X, which is known as a major monomer actin 
sequesterer, which is the main focus of RegeneRx Biopharmaceuticals. They have shown 
that TMSB4X promotes seemingly oncogenic cellular effects, which includes increased 
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cell migration, blood vessel formation, cell survival, stem cell differentiation. Therefore, 
it is currently on clinical trials to be for dermal and corneal repair. 
On the contrary, our functional analysis of TMSB4Y is consistent with tumor 
suppressive effects. When we overexpressed TMSB4Y in our Dox-inducible system in 
MCF-10A background, we observed altered cellular morphology, where cells become 
enlarged with aberrant morphology (Fig. 9), and also persistent reduced cell proliferation 
(Fig. 10). Because we saw a persistent reduction in cell proliferation after Dox-induction, 
we are currently looking at cell cycle analysis of the stable Dox-induced clones. 
TMSB4Y is highly homologous to TMSB4X, with a difference of only three out of 
44 amino acids. However, we show here that these X-Y homologues have fundamental 
differences, especially because the specific antibody for TMSB4Y does not recognize 
TMSB4X (Fig. 12) despite their high extent of homology. 
Interestingly, mammalian studies introduced a rising concept of antagonism 
between X-Y homologues, generally seen as genomic battles between the sex 
chromosomes [64, 65]. These studies infer that X homologues oppose Y homologues 
functionally, which is in consonance with our functional observations of TMSB4Y and 
functional reports of TMSB4X. To date, there is no report of direct interaction between 
TMSB4Y and monomeric actin. Therefore, we are currently trying to investigate this 
protein-protein interaction via immunoprecipitation assays and also via proximity ligation 
assay. We believe that TMSB4Y and TMSB4X might interact differently with actin. More 
comparative functional studies are required to explore and confirm this proposed 
opposing functional difference between TMSB4Y and TMSB4X. 
49 
 
Our functional analysis of TMSB4Y in the Dox-inducible system shows that 
TMSB4Y causes aberrant cellular morphology and reduced cell proliferation. In order to 
find the mechanism behind these effects, we performed RPPA on these Dox-inducible 
clones to investigate the global protein expression changes caused by the overexpression 
of TMSB4Y. Here, we have to note that caution has to be taken when analyzing RPPA 
data, because the specificity of the antibody optimized by the RPPA core facility at MD 
Anderson might be different towards different kinds of cell lines. Overall, subtle protein 
level changes were observed after Dox-induction in TmY1, and amongst several 
candidates that we are currently validating, we observed here that the Syk protein 
expression was modestly reduced after Dox-induction (Fig. 11).  Syk is the spleen 
tyrosine kinase, which is upregulated in T cell lymphoma, suggesting an oncogenic role 
in tumorigenesis, and various Syk inhibitors are currently available [66]. Our RPPA data 
suggests that overexpression of our proposed tumor suppressor candidate TMSB4Y led to 
reduced expression of the oncogenic Syk, further suggesting possible inter-regulatory 
effects between opposing oncogenic and tumor suppressive genes. These are initial 
results from our RPPA experiment and further analysis is needed to elucidate mechanistic 
details of our observations. 
Because our functional analysis of TMSB4Y suggests that it is a breast specific 
tumor suppressor, it will be informative to be able to knockout TMSB4Y in a normal male 
breast epithelial cell line, which is basically the male equivalent of the female MCF-10A 
nontumorigenic breast epithelial cell line. In future, perhaps this male equivalent of 
MCF-10A can also be created via spontaneously immortalizing normal male breast 
epithelial cells in long-term tissue cultures. It took about 800 days for MCF-10A to be 
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spontaneously formed and therefore, it might take about the same, a shorter, or perhaps a 
longer duration for male breast epithelial cells to become spontaneously immortalized 
[44]. Furthermore, we are also currently trying to establish stable expression clones of 
TMSB4Y in some female breast cancer cell lines to further validate its tumor suppressive 
role in breast cancer. 
In conclusion, our observation of ~15% in situ clonal loss of Y chromosome in 
MBC supports our hypothesis that the human Y chromosome is tumor suppressive in 
breast cancer. Furthermore, TMSB4Y might be a breast specific tumor suppressor gene on 
the human Y chromosome, and TMSB4Y might confer its tumor suppressive effects via 
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